Moderna
Search results
We at BioNTech believe that the immune system is the fundamental driver for therapeutic success in cancer, and infectious diseases and other serious diseases.
- Careers
Join us on our mission to improve global health by...
- Newsroom
Videos, photos, press releases or data sheets Learn more...
- Imprint
BioNTech SE An der Goldgrube 12 55131 Mainz Germany . Tel.:...
- Pipeline
Explore our product candidates. Based on our modular...
- Collaborators
The collaboration consists of two parts: BioNTech has a...
- History
The Pfizer-BioNTech COVID-19 vaccine is the first vaccine to...
- Careers
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, [12] and Christoph Huber, [13] with a seed investment of €150 million from MIG Capital and AT Impf. [14] The company's activities focus on the development and production of technologies and drugs for individualized cancer immunotherapy. [3]
With decades of deep immunology expertise and experience in developing and optimizing mRNA as part of its broad suite of novel technologies, the company is working with the global community to defeat life-threatening and serious diseases such as cancer, COVID-19, malaria and tuberculosis.
We aspire to find new and better ways to treat and prevent diseases. We aim to improve standards of care or establish new ones. We at BioNTech believe that the immune system is the fundamental driver for therapeutic success in cancer and infectious diseases.
Aug 18, 2022 · This article provides a summary of the interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19 issued by WHO Strategic Advisory Group of Experts on Immunization (SAGE).
Just six days later, on March 17, Pfizer signed a letter of intent with BioNTech to co-develop a potential COVID-19 vaccine2. In those early days, it was unclear how this new virus was transmitted, or how long it would last.
Nov 18, 2020 · The only Grade 3 (severe) solicited adverse events greater than or equal to 2% in frequency after the first or second dose was fatigue at 3.8% and headache at 2.0% following dose 2. Consistent with earlier shared results, older adults tended to report fewer and milder solicited adverse events following vaccination.
